Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 417 - 424 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2352 | MDL 28170 |
|
Potent, selective inhibitor of calpain and cathepsin B (Ki values are 10 and 25 nM respectively) that does not inhibit trypsin-like serine proteases. Rapidly penetrates the blood-brain barrier following systemic administration and displays neuroprotective effects in vivo.
|
|
| BCC2353 | PD 150606 |
|
Selective, cell-permeable non-peptide calpain inhibitor (K<sub>i</sub> values for <span class='symbol'>ν</span> and m-calpains are 0.21 and 0.37 <span class='symbol'>μ</span>M respectively). Targets the calcium binding sites of calpain. Demonstrates high specificity for calpains relative to other proteases, and is a non-competitive inhibitor with respect to the substrate.
|
|
| BCC2354 | PMPA (NAALADase inhibitor) |
|
Highly potent and selective inhibitor of glutamate carboxypeptidase 2 (GCP II/N-acetylated α-linked dipeptidase/NAALADase) with a Ki value of 275 pM. Neuroprotective; protects against glutamate-mediated motor neuron degeneration and reduces volume of injury following middle cerebral artery occlusion (MCAO).
|
|
| BCC2355 | ZJ 43 |
|
Potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (Ki values are 0.8 and 23 nM respectively) that inhibits the hydrolysis of NAAG (IC50 = 2.4 nM). Does not directly interact with NMDA or metabotropic glutamate receptors. Reduces neuronal degeneration in a rat model of traumatic brain injury (TBI) and reduces locomotor activity in the PCP-model of schizophrenia.
|
|
| BCC2356 | AZ 10417808 |
|
Selective non-peptide inhibitor of caspase-3 (K<sub>i</sub> = 247 nM); displays > 40-fold selectivity over caspases 1, 2, 6, 7 and 8 (K<sub>i</sub> > 10 <span class='symbol'>μ</span>M). Completely blocks staurosporine-induced intracellular DEVDase activity in SH-SY5Y cells (IC<sub>50</sub> = 14.9 <span class='symbol'>μ</span>M).
|
|
| BCC2357 | Ivachtin |
|
Potent, reversible inhibitor of caspase-3 (IC50 = 23 nM) that displays moderate selectivity over other caspases. Exhibits antiapoptotic activity in human Jurkat T cells treated with staurosporine; exhibits a higher level of protection than Z-VAD-FMK .
|
|
| BCC2358 | Ac-IEPD-AFC |
|
Peptide sequence shown to be preferred recognition motif for the serine protease granzyme B. Fluorogenic substrate.
|
|
| BCC2359 | Ac-LEHD-AFC |
|
Fluorogenic caspase substrate. Analog of the caspase-9 substrate, LEHD-AFC.
|
|